search

Active clinical trials for "Liver Cirrhosis"

Results 221-230 of 1394

Evaluation of Long Haul COVID-19 and Vaccine Immunogenicity in Patients With Liver Disease

COVID-19Chronic Liver Failure4 more

The project is essential to understand the impact of the COVID-19 pandemic in patients with Chronic Liver Disease (CLD). The impact has been felt due to direct risk of COVID infection in self, or in caregivers, lack of access to services during lockdown, interruptions in transplant listing and waitlist mortality. Briefly, the following points will be focused during the study. Long haul COVID-19 related symptoms. Impact on health and delay in interventions or drug therapy due to interruption of physical outpatient services. Impact on emergency admissions due to refractory ascites, new decompensation, variceal bleeding etc Impact on delayed transplant listing and waitlist mortality Impact on post-transplant patients with lack of access to drug monitoring/ physical OPD Impact on delay in interventions due to hepatobiliary malignancy. Effects of COVID-19 infection, vaccination (single dose, two doses) and no vaccination and protective antibody levels in patients with chronic liver disease and post-transplant recipients. Determination of dose protocol and need for booster vaccination in patients with CLD and post liver transplant recipients.

Recruiting17 enrollment criteria

The European NAFLD Registry

NAFLDNASH11 more

The European NAFLD Registry is a prospectively recruited, observational study supporting the study of the clinical phenotype, natural history, disease outcomes and pathophysiology of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. The ultimate goals are to better understand the drivers of interpatient variation in disease pathophysiology and severity and to utilise this information to develop and validate biomarkers that, singly or in combination, enable detection and monitoring of disease progression and/or from NAFL through NASH to fibrosis and cirrhosis.

Recruiting19 enrollment criteria

Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices...

Prevention of Esophageal VaricesNASH - Nonalcoholic Steatohepatitis1 more

This seamless, adaptive, two-stage, Phase 2b/3, randomized, double-blind, multicenter, parallel-groups, placebo-controlled study will assess the efficacy, safety, and tolerability of belapectin compared with placebo in patients with nonalcoholic steatohepatitis (NASH) cirrhosis and clinical signs of portal hypertension but without esophageal varices at baseline.

Active83 enrollment criteria

Use of Blood Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma (HCC)

HCCCirrhosis4 more

The objective of this observational study is to evaluate the clinical utility of the combined assay of 3 biomarkers: α-FP, α-FP-L3 and DCP (simultaneously measured by µTASWakoTM i30 automated in vitro diagnostic system) in high-risk subjects to develop this neoplasm. In particular, it aims to: Evaluate the clinical utility of the combined use of α-FP, α-FP-L3 and DCP in predicting the onset of HEPATOCARCINOMA (HCC); Evaluate the performance of GALAD and GALADUS scores in the early diagnosis of HCC; Evaluate the association between the levels of the three biomarkers (individually and in combination with each other) and the stage of HCC

Recruiting5 enrollment criteria

Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis...

CarcinomaHepatocellular7 more

The goal of this study is to evaluate whether the standardized liver cancer risk stratification management can effectively improve the early diagnosis rate of liver cancer in the targeted risk population in China.

Recruiting23 enrollment criteria

SGLT-2 Inhibitors in the Treatment of Ascites

Ascites HepaticCirrhosis2 more

The goal of this observational study is to test the efficacy of glyphozines (SGLT-2 inhibitors) in the control of ascites in patients with liver cirrhosis in class A6-B9, according to the Child-Pugh classification, and type 2 diabetes mellitus. The investigators will compare patients belonging to the intervention group (A), who will be given SGLT-2 inhibitors according to diabetology indications in addition to standard medical therapy for 6, with patients of the control group (B), who will, instead, continue with the standard medical therapy for 6 months. Standard medical therapy will include dietary sodium restriction, treatment with diuretics (furosemide and spironolactone), hypoglycemic therapy (metformin, insulin, or both) and other supportive care. The main questions aims of this study are: Compare the efficacy and safety of a therapeutic approach based on the administration of SGLT-2 inhibitors in addition to optimal medical therapy (MRA and loop diuretic) compared to traditional diuretic therapy only, in cirrhotic patients with saline retention and diabetes. Demonstrate better control of the glycemic profile in cirrhotic diabetic patients using SGLT-2 inhibitors.

Recruiting25 enrollment criteria

Atorvastatin Use and Portal Hypertension in Patients With Hepatitis B Virus-related Liver Cirrhosis:...

Hepatitis BPortal Hypertension

To evaluate whether atorvastatin can improve portal hypertension in patients with chronic hepatitis B related compensated cirrhosis with portal hypertension

Not yet recruiting18 enrollment criteria

Pentoxifylline Plus Carvedilol vs Carvedilol Monotherapy in Preventing New Decompensation in Stable...

Liver Cirrhosis

Cirrhotics with decompensation have increased risk of morbidity and mortality. There is increased portal pressure leading to decompensation. Carvedilol is a standard therapy given to cirrhotic patient with clinically significant portal hypertension to reduce portal pressure. Pentoxifylline is a nonspecific phosphodiesterase inhibitor with anti-inflammatory properties. It reduces portal hypertension, decreases lipopolysaccharide-induced liver injury, improves nonalcoholic steatohepatitis, prevents development of HRS in ascites and SAH, prevents hepatopulmonary syndrome. Investigator want to study whether addition of pentoxifylline to carvediolol vs carvedilol monotherapy reduces the risk of mortality and further decompensation in cirrhotics with prior decompensation.

Not yet recruiting20 enrollment criteria

The Visceral Adiposity Measurement and Observation Study

HIVHIV-Infections17 more

The Visceral Adiposity Measurement and Observation Study

Recruiting16 enrollment criteria

Continuous Versus Bolus Infusion of Terlipressin for Portal Hypertension Related Bleeding in Liver...

Liver CirrhosisPortal Hypertension3 more

Terlipressin is the mainstay drug for the treatment of acute variceal bleeding in liver cirrhosis. According to the drug instructions, intravenous bolus infusion is the standard approach of terlipressin. It remains unclear about whether or not continuous infusion of terlipressin should be considered.

Not yet recruiting8 enrollment criteria
1...222324...140

Need Help? Contact our team!


We'll reach out to this number within 24 hrs